论文部分内容阅读
比较利拉鲁肽与格列美脲对血糖控制不佳的2型糖尿病伴肥胖患者疗效。方法 64例单用二甲双胍血糖控制不佳的2型糖尿病伴肥胖患者,在保留二甲双胍1500mg/日基础上,随机分为利拉鲁肽组和格列美脲组,治疗24周,观察患者血糖、HbA1c、BMI、血脂及低血糖发生率。结果两组治疗对改善FBG、2hPG、HbA1c疗效相当,对HDL-C无明显改善。利拉鲁肽还可降低BMI、TG、TC、LDL-C,且低血糖发生率更低。结论利拉鲁肽较格列美脲更适于2型糖尿病伴肥胖患者。
To compare the efficacy of liraglutide and glimepiride in obese type 2 diabetic patients with poor glycemic control. Methods Sixty-four patients with type 2 diabetes mellitus who had poorly controlled glycemic control with metformin were randomly divided into liraglutide and glimepiride groups on the basis of 1500mg / day of metformin. After 24 weeks of treatment, blood glucose, HbA1c, BMI, lipids and hypoglycemia incidence. Results The two groups of treatment had the same effect on improving FBG, 2hPG and HbA1c, but no significant improvement on HDL-C. Liraglutide can also reduce BMI, TG, TC, LDL-C, and lower incidence of hypoglycemia. Conclusion Liraglutide is more suitable than glimepiride for type 2 diabetes with obesity.